The October 2017 issue of Pharmafocus is now live!
pharmafile | September 26, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â ABPI, EMA, PharmafocusÂ
The October edition of Pharmafocus is now live! You can read it here.
Allergan has found itself in the firing line after its latest marketing move. Not even a full year from CEO Brent Saunders’ announcement of a ‘social contract’ with patients promising to cap price increases, the company has taken the unprecented step of selling its drug rights to a Native American tribe in order to dodge direct competition. Unsurprisingly, patients and competitors are not happy. Get up to speed with our front page story.
In the UK, an industry worried and uncertain over Brexit welcomed the release of Sir John Bell’s Life Sciences Industrial Strategy. We spoke to ABPI Chief Executive Mike Thompson to get his thoughts on a report he called “the right intervention at the right time”.
Across in the US, researchers at the University of Texas have developed a ‘pen’ device which can identify cancerous tissue in just ten seconds. The implications of the technology on cancer treatment are potentially huge, and we spoke to the team to get the full story on what to expect from the device.
As the next home of the EMA headquarters is set to be revealed this month, forced from its current London location by the Brexit referendum, we look at the 19 competing EU member states with exclusive interviews to discover what is being brought to the negotiating table. Find out everything you need to know in the run-up to the final vote in our special feature.
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
NICE issues positive final guidance for treatment of Duchenne Muscular Dystrophy from Santhera
Santhera Pharmaceuticals has received positive final guidance from the National Institute for Care and Excellence …
Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …
